[April 29, 2015] Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that the European Patent Office (EPO) has upheld the validity of the ... TMC Net, 3 weeks ago
Rosetta Genomics Patent on Therapeutic Use of miR-34a Upheld by European Patent Office in Opposition Proceedings - PharmiWeb, 4 weeks ago
Rosetta Genomics USA : Patent on Therapeutic Use of miR-34a Upheld by European Patent Office in Opposition Proceedings - 4 Traders, 4 weeks ago
More from: CNBC, Minyanville...and 28 other sources
MOMENTA PHARMACEUTICALS INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q and the ...Pharmacy Choice, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!